21 May 2009
Optimal MPA, MPAG levels at the early period after kidney transplantation as the key contributors to improving long-term outcomes
T Baczkowska, A Sadowska, J Majchrzak, A Perkowska-Ptasińska, Z Lewandowski, T Cieciura, J Pazik, E Ważna, E Nowacka Cieciura, A Chmura, M DurlikAnn Transplant 2009; 14(1): 22-22 :: ID: 880277
Abstract
Background: Suboptimal MPA, MPAG levels are associated with significant
increases in graft loss. Purpose: to assess the influence of MPA, MPAG - Co
levels on GFR level and histological changes in the protocol biopsies in kidney allograft recipients.
Material/Methods: In a prospective study of 42 low-risk patients receiving MMF,
prednisone and a low or normal CsA dose we performed histological assessment according to Banff'97 classification in protocol biopsies before Tx and then at 3, 12, 36 months after Tx, we also assessed GFR at 1, 3, 12, 36 and 60 months after Tx and MPA (ELISA), MPAG (HPLC/UV) Co levels at day 7 and at 1, 3, 12, 36 months after Tx. Statistical analysis was performed with the aid of Generalized Additive Models (SAS System) and Spearman correlation.
Results: We observed significant relationships between MPA, MPAG Co levels and the subclinical rejection episodes (SCR), ci, ct, ah, CAN in the protocol biopsies at 36 month after Tx. In detail: MPA Co level at day 7 after Tx below 1.5 μg/mL was associated with increased risk of SCR (pnl<0.03), ci ≥2 (pnl<0.05), CAN ≥2 (pnl <0.04) and with ah ≥2 (pnl<0.07). MPAG Co level at day 7 after Tx above 100-150 μg/mL was associated with decreased risk of ct ≥2 (pnl <0.01), ci ≥2 (pnl <0.04), CAN ≥2 (pnl <0.04). We also observed significant positive correlations between MPA Co level and negative significant correlations
between MPAG Co level at 1 month after Tx and GFR at 1, 3, 12 and 36 month after Tx.
Conclusions: Optimal MPA exposure in the early post-transplant period may improve renal graft outcomes
Keywords: Immunosuppression, Kidney Transplantation
Most Viewed Current Articles
26 Jan 2022 : Review article
Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive ModelsDOI :10.12659/AOT.934924
Ann Transplant 2022; 27:e934924
24 Aug 2021 : Review article
Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future PerspectivesDOI :10.12659/AOT.931664
Ann Transplant 2021; 26:e931664
29 Dec 2021 : Original article
Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...DOI :10.12659/AOT.933588
Ann Transplant 2021; 26:e933588
15 Mar 2022 : Case report
Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...DOI :10.12659/AOT.935860
Ann Transplant 2022; 27:e935860